Pfizer (PFE) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
PFIZER REPORTS THIRD-QUARTER 2018 RESULTS
October 30, 2018 6:45 AM EDTThird-Quarter 2018 Revenues of $13.3 Billion, Reflecting 2% Operational Growth Third-Quarter 2018 Reported Diluted EPS(1) of $0.69, Adjusted Diluted EPS(2) of $0.78 Narrowed Certain 2018 Financial Guidance Ranges; Midpoint of Updated Adjusted Diluted EPS(2) Guidance Range of $2.98 to $3.02 is Unchanged from July 2018 Repurchased $1.1 Billion of Common Stock in Third-Quarter 2018 and $9.0 Billion to Date in 2018; Now Expect to Repurchase Approximately $12 Billion of Shares in 2018
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2018 and narrowed certain 2018 financial guidance ranges.
Results for the third quarter and first nine months of 2018 and 2017(3) are summarized below.
OVERALL RESULTS... More